This inventor holds 1 USPTO granted patent. Top assignee: Dana-Farber-Cancer Institute Inc.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Wenchao Wu: Innovator in Targeted Degradation Therapies
Introduction
Wenchao Wu is a notable inventor based in Brookline, MA (US). He has made significant contributions to the field of biomedical research, particularly in the development of targeted therapies. His work focuses on innovative compounds that can effectively address complex diseases.
Latest Patents
Wenchao Wu holds a patent for "Compounds for targeted degradation of interleukin-2-inducible T-cell kinase and methods of use." This patent discloses bispecific compounds, known as degraders, that target ITK or a zinc finger (ZnF) protein for degradation. The patent also includes pharmaceutical compositions containing these degraders and outlines methods for using the compounds to treat diseases and disorders characterized or mediated by ITK or ZnF protein activity. He has 1 patent to his name.
Career Highlights
Wenchao Wu is affiliated with the Dana-Farber Cancer Institute Inc., where he continues to advance his research and contribute to the field of cancer treatment. His work is instrumental in developing new therapeutic strategies that can improve patient outcomes.
Conclusion
Wenchao Wu's innovative approach to targeted degradation therapies showcases his commitment to advancing medical science. His contributions are paving the way for new treatments that could significantly impact the lives of patients suffering from various diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile